GlobeNewswire · Press release
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. Short interest is 9.68% of float with a 0.68% borrow fee. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 32.6 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price — · As of —
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
BBOT · NASDAQ · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
— · Industry comparison not available
— · Smart-money activity not available
All smart-money activity →GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.